2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1756

Systematic Review of the Clinical Effectiveness of Treatments in Eosinophilic Granulomatosis with Polyangiitis

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 1642

Systematic Screening of Comorbidities Improves Vaccination Rates, Skin Cancer Screening and Vitamin D Supplementation in Patients with Axial Spondyloarthritis: Results of a Prospective, Controlled ,One Year Randomised Trial

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1371

Systemic Exposure of Triamcinolone Acetonide Following Bilateral Injection of Extended-Release Triamcinolone Acetonide and Standard Triamcinolone in Patients with Bilateral Knee Osteoarthritis

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1290

Systemic Inflammation and Atherosclerosis in Patients with Gout. Results from the NOR-Gout Study

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1687

Systemic Lupus Flares Based on BILAG and Sledai Rules Are Inconsistent, but May be Better Understood Using Visual Analogue Scales

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1103

Systemic Sclerosis Has a Distinct Serum Protein Profile That Correlates with Its Clinical Manifestations

Systemic Sclerosis and Related Disorders – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 1440

Systemic Sclerosis in Pediatric Patients: An Epidemiological Study in a Large Insured Population in the US

Pediatric Rheumatology – Clinical Poster I – ARHP

9:00AM-11:00AM: Abstract Number: 1039

Tenofovir Induces Osteopenia and Dipyridamole, an Inhibitor of the Ent-1 Nucleoside Transporter, Reverses the Osteopenic Effect of Tenofovir In Vivo

Osteoarthritis and Joint Biology – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 1038

Tenofovir, a Nucleoside Analog Reverse Transcriptase Inhibitor for Treatment of HIV, Promotes Osteoclast Differentiation and Decreases Osteoblast Formation By a Mechanism Depending on ATP Release and Adenosine

Osteoarthritis and Joint Biology – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 1202

Tenosynovial Aspiration By Ultrasound Guidance: Even Small Volumes Can Have a Big Impact

Imaging of Rheumatic Diseases Poster II: Ultrasound

9:00AM-11:00AM: Abstract Number: 1203

Tenosynovitis Detected By Ultrasound Predicts Arthritis Onset in Individuals at Risk of Developing Rheumatoid Arthritis

Imaging of Rheumatic Diseases Poster II: Ultrasound

9:00AM-11:00AM: Abstract Number: 1606

The 66/68 Joint Count for the Measurement of MSK Disease Activity/Peripheral Joint Activity in Psa: A Grappa-Omeract Working Group Initiative

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1041

The Anti-Adamts-5 Nanobody®, M6495, Protects Against Cartilage Breakdown in Cartilage and Synovial Joint Tissue Explant Models

Osteoarthritis and Joint Biology – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 1267

The Association between Clinically Suspect Arthralgia and Adipokines in Obese Patients

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1698

The Association between Periodontitis and the Disease Activity of Systemic Lupus Erythematosus: A Cross-Sectional Study

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].